Clinical trial · Observational
Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
Observational Study Evaluating the Efficacy and Tolerability of Anticancer Drug Therapies Adopted for the Treatment of Gynecologic and Breast Cancers in Clinical Practice Compared with the Results of Registration Studies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Early Stage Breast Cancer (Stage 1-3) | — | UNRESOLVED | — |
| Breast Cancer Metastatic | — | UNRESOLVED | — |
| Cervical Carcinoma | Cervical Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oncologic drug administered for treatment of gynecologic cancer | Drug | — | UNRESOLVED |
| Oncologic drugs administered for treatment of breast cancer | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- retrospective cohort
- description
- In this cohort data will be recorded retrospectively
- interventionNames
- Drug: Oncologic drugs administered for treatment of breast cancer
- Drug: Oncologic drug administered for treatment of gynecologic cancer
- label
- prospective cohort
- description
- In this cohort data will be recorded prospectively
- interventionNames
- Drug: Oncologic drugs administered for treatment of breast cancer
- Drug: Oncologic drug administered for treatment of gynecologic cancer
Primary outcomes (1)
- measure
- DFS
- timeFrame
- From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic; * Patients who have received treatment for breast cancer or gynecologic cancer since January 2010; * Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data. Exclusion Criteria: * no exclusion criteria
References
Publications (0)
Data not yet available